BioLineRx Ltd. (TLV:BLRX)
2.100
+0.100 (4.76%)
Aug 14, 2025, 5:24 PM IDT
BioLineRx Revenue
BioLineRx had revenue of $304.00K USD in the quarter ending June 30, 2025, a decrease of -94.36%. This brings the company's revenue in the last twelve months to $17.25M, up 1.19% year-over-year. In the year 2024, BioLineRx had annual revenue of $28.94M with 502.92% growth.
Revenue (ttm)
$17.25M
Revenue Growth
+1.19%
P/S Ratio
0.92
Revenue / Employee
$616.11K
Employees
28
Market Cap
53.71M ILS
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical Industries | 56.02B |
Danel (Adir Yeoshua) | 2.81B |
Kamada | 622.70M |
Bait Bakfar | 104.50M |
SofWave Medical | 234.12M |
BrainsWay | 161.81M |
Novolog (Pharm-Up 1966) | 2.07B |
Ilex Medical | 922.08M |
BioLineRx News
- 13 hours ago - BioLineRx GAAP EPS of $0.00, revenue of $5.39M - Seeking Alpha
- 13 hours ago - BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 16 hours ago - Earnings Scheduled For August 14, 2025 - Benzinga
- 1 day ago - BioLineRx Q2 2025 Earnings Preview - Seeking Alpha
- 7 days ago - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - PRNewsWire
- 2 months ago - Why Is Nano-Cap BioLineRx Stock Surging On Friday? - Benzinga
- 2 months ago - Why Is Nano-Cap BioLineRx Stock Surging On Friday? - Benzinga
- 2 months ago - BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting - PRNewsWire